Adial Pharmaceuticals Wt Stock EBITDA
Adial Pharmaceuticals WT fundamentals help investors to digest information that contributes to Adial Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Adial Stock. The fundamental analysis module provides a way to measure Adial Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adial Pharmaceuticals stock.
Adial |
Adial Pharmaceuticals WT Company EBITDA Analysis
Adial Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Adial Pharmaceuticals EBITDA | (13.78 M) |
Most of Adial Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adial Pharmaceuticals WT is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Adial Pharmaceuticals WT reported earnings before interest,tax, depreciation and amortization of (13.78 Million). This is much lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is notably higher than that of the company.
Adial EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adial Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics of similar companies.Adial Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Adial Fundamentals
Number Of Shares Shorted | 506 | |||
EBITDA | (13.78 M) | |||
Net Income | (12.73 M) | |||
Total Debt | 207.38 K | |||
Cash Flow From Operations | (11.19 M) | |||
Total Asset | 5.73 M | |||
Retained Earnings | (63.67 M) | |||
Working Capital | 2.99 M | |||
Z Score | -22.86 | |||
Net Asset | 5.73 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Adial Stock
If you are still planning to invest in Adial Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adial Pharmaceuticals' history and understand the potential risks before investing.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |